RxDoctor Payments Data

Kavita Gupta, MD

Geriatric Medicine · Cedar Grove, NJNPI 1073833554

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 18 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by AstraZeneca at 33.7% of the total. Reporting peaked in 2021 at $752 and has fallen 97.3% since, to $21 in 2023.

$1,814in general payments, 2019–2025

Across 18 payments — averaging $100.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$612
  • Abiomed$221
  • Boston Scientific$186
  • Balt USA, LLC$136
  • Boehringer Ingelheim$125
  • Novartis$125
  • plus $410 from 5 others

What the payments were for

  • Food & beverage$1,814100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,814 in reported general payments places this provider in the 75th percentile of 165 geriatric medicine providers in New Jersey.

See all geriatric medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$97,956
Medicare patients
73
Services billed
968

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban55$39,620
Glatiramer Acetate28$35,276
TrulicityDulaglutide11$11,520
JanuviaSitagliptin Phosphate21$9,808
Milrinone In 5% DextroseMilrinone Lactate/D5w69$9,215
XareltoRivaroxaban27$7,989
FarxigaDapagliflozin Propanediol15$7,887
RhopressaNetarsudil Mesylate20$6,957
TradjentaLinagliptin15$5,470
Divalproex Sodium90$5,219
Mirtazapine105$3,471
Levetiracetam89$3,453
Paliperidone ErPaliperidone12$2,945
Sevelamer Carbonate15$2,828
Atorvastatin Calcium208$2,805

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$612$7,88715 claims
Boehringer IngelheimTradjenta$125$5,47015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 165 geriatric medicine providers in New Jersey.

Other geriatric medicine in Cedar Grove

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →